Assembly Biosciences Valuation
| ASMB Stock | USD 25.78 0.07 0.27% |
At this time, the firm appears to be undervalued. Assembly Biosciences shows a prevailing Real Value of $30.69 per share. The current price of the firm is $25.78. Our model approximates the value of Assembly Biosciences from analyzing the firm fundamentals such as Return On Equity of -0.37, profit margin of (1.04) %, and Current Valuation of 176.86 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Assembly Biosciences' valuation include:
Price Book 2.2259 | Enterprise Value | Enterprise Value Ebitda 0.4244 | Price Sales 10.6792 | Enterprise Value Revenue 4.7554 |
Undervalued
Today
Please note that Assembly Biosciences' price fluctuation is not too volatile at this time. Calculation of the real value of Assembly Biosciences is based on 3 months time horizon. Increasing Assembly Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Assembly Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Assembly Stock. However, Assembly Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.78 | Real 30.69 | Target 47.75 | Hype 26.09 | Naive 24.93 |
The real value of Assembly Stock, also known as its intrinsic value, is the underlying worth of Assembly Biosciences Company, which is reflected in its stock price. It is based on Assembly Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Assembly Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Assembly Biosciences helps investors to forecast how Assembly stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Assembly Biosciences more accurately as focusing exclusively on Assembly Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Assembly Biosciences' intrinsic value based on its ongoing forecasts of Assembly Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Assembly Biosciences' closest peers. If more than one evaluation category is relevant for Assembly Biosciences we suggest using both methods to arrive at a better estimate.
Assembly Biosciences Cash |
|
Assembly Biosciences Total Value Analysis
Assembly Biosciences is presently expected to have valuation of 176.86 M with market capitalization of 397.17 M, debt of 3.09 M, and cash on hands of 116.69 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Assembly Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
176.86 M | 397.17 M | 3.09 M | 116.69 M |
Assembly Biosciences Investor Information
About 32.0% of the company shares are held by company insiders. The book value of Assembly Biosciences was presently reported as 11.55. The company recorded a loss per share of 4.6. Assembly Biosciences had not issued any dividends in recent years. The entity had 1:12 split on the 12th of February 2024. Based on the key indicators related to Assembly Biosciences' liquidity, profitability, solvency, and operating efficiency, Assembly Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Assembly Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Assembly Biosciences has an asset utilization ratio of 23.93 percent. This suggests that the Company is making $0.24 for each dollar of assets. An increasing asset utilization means that Assembly Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Assembly Biosciences Profitability Analysis
Based on Assembly Biosciences' profitability indicators, Assembly Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Assembly Biosciences' ability to earn profits and add value for shareholders.Net Loss | First Reported 2008-12-31 | Previous Quarter -10.2 M | Current Value -9.2 M | Quarterly Volatility 10.8 M |
For Assembly Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Assembly Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Assembly Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Assembly Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Assembly Biosciences over time as well as its relative position and ranking within its peers.
Assembly Biosciences Earnings per Share Projection vs Actual
The next projected EPS of Assembly Biosciences is estimated to be -0.9275 with future projections ranging from a low of -1.0775 to a high of -0.825. Assembly Biosciences' most recent 12-month trailing earnings per share (EPS TTM) is at -4.6. Please be aware that the consensus of earnings estimates for Assembly Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Assembly Biosciences Earnings Estimation Breakdown
The calculation of Assembly Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Assembly Biosciences is estimated to be -0.9275 with the future projection ranging from a low of -1.0775 to a high of -0.825. Please be aware that this consensus of annual earnings estimates for Assembly Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.08 Lowest | Expected EPS | -0.82 Highest |
Assembly Biosciences Earnings Projection Consensus
Suppose the current estimates of Assembly Biosciences' value are higher than the current market price of the Assembly Biosciences stock. In this case, investors may conclude that Assembly Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Assembly Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 4 | 67.48% | -0.72 | -0.9275 | -4.6 |
Assembly Biosciences Ownership Allocation
Assembly Biosciences holds a total of 15.82 Million outstanding shares. Over half of Assembly Biosciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. On February 10, 2021, Representative Chris Jacobs of US Congress acquired under $15k worth of Assembly Biosciences's common stock.Assembly Biosciences Profitability Analysis
The company reported the previous year's revenue of 28.52 M. Net Loss for the year was (40.18 M) with loss before overhead, payroll, taxes, and interest of (24.65 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Assembly Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Assembly Biosciences and how it compares across the competition.
About Assembly Biosciences Valuation
The stock valuation mechanism determines Assembly Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Assembly Biosciences. We calculate exposure to Assembly Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Assembly Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 32.8 M | 34.4 M | |
| Pretax Profit Margin | (1.61) | (1.69) | |
| Operating Profit Margin | (1.83) | (1.92) | |
| Net Loss | (1.62) | (1.70) | |
| Gross Profit Margin | (6.70) | (7.04) |
Assembly Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Assembly Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Assembly we look at many different elements of the entity such as Assembly's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Assembly Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Assembly Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Assembly Biosciences' worth.Complementary Tools for Assembly Stock analysis
When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |